Cannabis Science Appoints Richard Ogden, PhD, Former Director of Scientific Affairs, HIV, Pfizer, as Chief Scientific Officer

 Cannabis Science Appoints Richard Ogden, PhD, Former Director of Scientific
              Affairs, HIV, Pfizer, as Chief Scientific Officer

PR Newswire

COLORADO SPRINGS, Colo., Feb. 27, 2013

COLORADO SPRINGS, Colo., Feb. 27, 2013 /PRNewswire/ -- Cannabis Science, Inc.
(NASDAQ OTC: CBIS) is pleased to announce the appointment of Richard Ogden,
Ph.D., Former Director of Scientific Affairs, HIV, Pfizer, as Chief Scientific
Officer of Cannabis Science. Dr. Ogden's knowledge, experience and success in
the discovery, development and commercialization of new therapeutics for HIV
and cancer will enhance the Company's novel clinical research and development
programs on phytocannabinoid-based drugs for HIV, Kaposi's Sarcoma (KS), and
basal/squamous cell carcinomas.

"I am delighted to be working with the team at Cannabis Science to develop
pioneering preclinical and clinical research programs on
phytocannabinoid-based products for serious unmet medical needs. The pathway
for the clinical development and commercialization of phytocannabinoids has
already been established outside the U.S. I look forward to the further
investigation of this class of compounds in HIV and cancer," said Dr. Ogden.

Dr. Ogden co-founded RORR Inc., a medical, scientific consulting and education
company contracted by U.S. and European-based clients, including the
International AIDS Society. RORR provides consulting for companies with a
focus on viral infectious disease including HIV, Hepatitis C and respiratory

Beginning his prestigious career as a Post Graduate Chemist at Cambridge
University, Dr. Ogden then held several positions at Agouron Pharmaceuticals
including Principal Scientist/Manager, New Projects Research, and Director and
Senior Director of Scientific Development. Dr. Ogden was also the Senior
Director of Scientific Affairs, HIV US Medical at Pfizer Inc.

Dr. Ogden was a team member in the HIV project that led to the discovery and
development of Nelfinavir (Viracept).

In working with Pfizer, he had an additional opportunity to work with the
Pfizer Foundation in its support of the Academic Alliance and its efforts in
Uganda, and with Corporate Philanthropy, in its support of the World Economic
Forum and the Global Business Council.

Dr. Ogden received his bachelor's degree in natural sciences and doctorate in
synthetic organic chemistry at Cambridge University. His academic career
started with postdoctoral research studying RNA transcription and processing
at the University of California, San Diego, following which he undertook
independent research, funded by the National Science Foundation, in the area
of protein and RNA structure-function relationships at the University of
California, San Diego and the Agouron Institute.

"Dr. Ogden's experience in advising pharmaceutical and biotech companies on
strategic planning for clinical research programs and product development in
the antiviral and oncological therapeutic areas, make him ideally situated for
the position of Chief Scientific Officer of Cannabis Science," stated Dr.
Robert Melamede, President and CEO of Cannabis Science.

About CS-TATI-1

Cannabis Science's research of CS-TATI-1 will be targeted to newly diagnosed
patients infected with drug resistant virus, treatment experienced patients
with drug-resistant HIV strains, and those intolerant of currently available
therapies. Cannabis Science will be pursuing a wide range of NIH-based Federal
Research Programs such as RO1's, PO1's and SBIRS which exist to support
preclinical development of target validation and proof of concept studies.
These studies will be implemented through collaborations with leading
scientific institutions. Cannabis Science will also be pursuing other clinical
research collaborations including the AIDS Clinical Trials Groups (ACTG), the
Canadian AIDS Trial Network (CATN) and the European AIDS Trial Network (EATN).

About CS-S/BCC-1

Cannabis Science is currently working to develop preclinical investigations of
CS-S/BCC-1 treatment of basal and squamous cell carcinomas. The Company has
begun preclinical investigations, which are being initiated in Europe for
squamous/basal cell carcinomas and Kaposi's Sarcoma based on inhibition of
carcinogenicity utilizing cannabinoids that have been demonstrated in recent
studies to significantly affect tumor necrosis.

About Cannabis Science, Inc.

Cannabis Science, Inc. is at the forefront of cannabinoid research and
development for unmet medical needs. The Company works with leading experts in
HIV and cancer drug development, medicinal characterization, and clinical
research to develop, produce, and commercialize phytocannabinoid-based
pharmaceutical products.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of
Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Act of 1934. A statement containing works such as "anticipate," "seek,"
"intend," "believe," "plan," "estimate," "expect," "project," "plan," or
similar phrases may be deemed "forward-looking statements" within the meaning
of the Private Securities Litigation Reform Act of 1995. Some or all of the
events or results anticipated by these forward-looking statements may not
occur. Factors that could cause or contribute to such differences include the
future U.S. and global economies, the impact of competition, and the Company's
reliance on existing regulations regarding the use and development of
cannabis-based drugs. Cannabis Science, Inc. does not undertake any duty nor
does it intend to update the results of these forward-looking statements.


Cannabis Science Inc.
Dr. Robert J. Melamede, 1-888-889-0888
President & CEO


Robert Kane, 1-561-234-6929
VP Investor Relations

SOURCE Cannabis Science, Inc.

Press spacebar to pause and continue. Press esc to stop.